CX 2014 Presentations 2017-08-01T13:03:35+00:00

CX 2014 Presentations

CX37
Vascular & Endovascular Consensus Update Saturday 05 April

Chairman Roger Greenhalgh, London, United Kingdom 08:00 to 08:35
Duplex ultrasound Malcolm Simms, Birmingham, United Kingdom 08:00 to 08:05
Magnetic resonance angiography David Kessel, Leeds, United Kingdom 08:05 to 08:10
CT angiography Jacob Sosna, Jerusalem, Israel 08:10 to 08:15
Intravascular digital subtraction angiography Johannes Gahlen, Ludwigsburg, Germany 08:15 to 08:20
Follow-up in and around a stent with ultrasound compared to angiography Serge Kownator, Thionville, France 08:20 to 08:25
Interactive audience participation 08:25 to 08:35
Chairman Roger Greenhalgh, London, United Kingdom 08:35 to 09:20
Chairman Ian Franklin, London, United Kingdom 08:35 to 09:20
Vascular complications in athletes Jonathan Beard, Sheffield, United Kingdom 08:35 to 08:40
Platelet responsiveness for clopidogrel treatment of peripheral arterial procedures Konstantinos Katsanos, London, United Kingdom 08:40 to 08:45
Role and relevance of patency in claudicants Iris Baumgartner, Bern, Switzerland 08:45 to 08:50
Interactive audience participation and consensus vote 08:50 to 09:00
For the motion: Supervised exercise, smoking cessation and best medical treatment should precede intervention Cliff Shearman, Southampton, United Kingdom 09:00 to 09:05
Against the motion: Supervised exercise, smoking cessation and best medical treatment should precede intervention Marc Bosiers, Dendermonde, Belgium 09:05 to 09:10
Interactive audience participation and consensus vote 09:10 to 09:20
Chairman Jonathan Beard, Sheffield, United Kingdom 09:20 to 10:00
Zilver PTX- 4-year results Michael Dake, Stanford, United States 09:20 to 09:27
Zilver PTX vs. Zilver Flex 28cm Thomas Zeller, Bad Krozingen, Germany 09:27 to 09:34
Interactive audience participation and consensus vote 09:34 to 09:40
New approach to superficial femoral artery reconstruction using over the wire sutureless distal anastomosis Jean Bismuth, Houston, United States 09:40 to 09:47
Stenting the superficial femoral artery 40-180mm - DURABILITY+ study Marc Bosiers, Dendermonde, Belgium 09:47 to 09:54
Interactive audience participation and consensus vote 09:54 to 10:00
Chairman Roger Greenhalgh, London, United Kingdom 10:30 to 11:40
An individualisation approach to surgical arterial bypass - choosing the optimal revascularisation option for each patient Edward Woo, Washington, United States 10:30 to 10:40
Use of a flexible ePTFE ?Nitinol dual component stent for superficial femoral artery lesions at one year Andrej Schmidt, Leipzig, Germany 10:40 to 10:50
4EVER study ? two-year data Marc Bosiers, Dendermonde, Belgium 10:50 to 11:00
Reasons to shift towards a non-stent-first-line approach in the modern era Sumaira Macdonald, Sunnyvale, United States 11:00 to 11:10
Atherectomy with drug coated balloon vs. drug coated balloon ? DEFINITIVE AR Thomas Zeller, Bad Krozingen, Germany 11:10 to 11:20
Bioresorbable developments: "Leave nothing behind" Andrew Holden, Auckland, New Zealand 11:20 to 11:30
Interactive audience participation and consensus vote 11:30 to 11:40
Chairman Roger Greenhalgh, London, United Kingdom 11:40 to 12:30
ILLUMENATE study on drug coated balloon - first-in-human 12-month outcomes Patrick Peeters, Bonheiden, Belgium 11:40 to 11:50
LEVANT 2 - a discussion of data and study design Dierk Scheinert, Leipzig, Germany 11:50 to 12:00
Drug eluting balloon vs. standard balloon angioplasty- one-year results of the IN.PACT superficial femoral artery randomised trial Gunnar Tepe, Rosenheim, Germany 12:00 to 12:10
The role of the drug-eluting balloon for TASC C & D lesions Andrej Schmidt, Leipzig, Germany 12:10 to 12:20
Interactive audience participation and consensus vote 12:20 to 12:30
Chairman Cliff Shearman, Southampton, United Kingdom 13:30 to 13:55
Algorithm of care Peter Gaines, Sheffield, United Kingdom 13:30 to 13:36
Status of modern endovascular therapies in claudicants - an evidence appraisal William Gray, New York, United States 13:36 to 13:42
Role of drug eluting balloon for in-stent restenosis Thomas Zeller, Bad Krozingen, Germany 13:42 to 13:48
Interactive audience participation 13:48 to 13:55
Chairman Cliff Shearman, Southampton, United Kingdom 13:55 to 14:20
Self-expanding stent use for popliteal lesions- DURABILITY-POP study Patrick Peeters, Bonheiden, Belgium 13:55 to 14:01
Orthopaedic popliteal artery injury Martin Bjorck, Uppsala, Sweden 14:01 to 14:07
Long-term outcomes and sac shrinkage after endovascular popliteal aneurysm exclusion Franco Grego, Padova, Italy 14:07 to 14:13
Interactive audience participation 14:13 to 14:20
Chairman Iris Baumgartner, Bern, Switzerland 14:20 to 15:00
Assessment, wound care and urgent revascularisation of the diabetic foot Michael Edmonds, London, United Kingdom 14:20 to 14:26
The value of angiosome definition and saving ischaemic and diabetic feet Christopher Attinger, Washington, United States 14:26 to 14:32
Antibiotic therapy is to treat infection, not to heal wounds Benjamin Lipsky, Seattle, United States 14:32 to 14:38
Interactive audience participation and consensus vote 14:38 to 14:45
For the motion: Topical negative pressure therapy should be used routinely for wound healing in the diabetic foot Michael Edmonds, London, United Kingdom 14:45 to 14:50
Against the motion: Topical negative pressure therapy should be used routinely for wound healing in the diabetic foot Cliff Shearman, Southampton, United Kingdom 14:50 to 14:55
Interactive audience participation and consensus vote 14:55 to 15:00
Chairman Iris Baumgartner, Bern, Switzerland 15:00 to 15:30
BASIL 2 - randomised controlled trial of endovascular vs. bypass for below-the-knee Andrew Bradbury, Bordesley Green, United Kingdom 15:00 to 15:10
Interactive audience participation and consensus vote 15:20 to 15:30
Chairman Thomas Zeller, Bad Krozingen, Germany 16:00 to 16:40
Stem cell therapy - a new standard for non-option critical limb ischaemia Vaclav Prochazka, Ostrava, Czech Republic 16:00 to 16:06
The value of the below-the-knee level loop technique of foot artery reconstruction Eric Ducasse, Bordeaux, France 16:06 to 16:12
Prospective multicentre results of drug-eluting stenting for below-the-knee arteries up to 5mm Marc Bosiers, Dendermonde, Belgium 16:12 to 16:18
Outcomes for drug-coated balloons below the knee: the need to prove benefit William Gray, New York, United States 16:18 to 16:24
The CRITISCH Registry: which is the best treatment for diabetic, renal and female patients: open, endovascular or no intervention Giovanni Torsello, Muenster, Germany 16:24 to 16:30
Interactive audience participation and consensus vote 16:30 to 16:40
Chairman Frans Moll, Utrecht, Netherlands 16:40 to 17:11
The place of CT angiography for carotid evaluation Hans-Christoph Becker, Munich, Germany 16:54 to 17:01
Imaging consensus 17:01 to 17:11
Chairman Frans Moll, Utrecht, Netherlands 17:11 to 18:08
Delphi criteria for patient selection for either carotid stenting or carotid endarterectomy Sumaira Macdonald, Sunnyvale, United States 17:11 to 17:18
Rapid interventions prevent more strokes: delay should not be tolerated Ross Naylor, Leicester, United Kingdom 17:18 to 17:25
Long-term data on ICSS Martin Brown, London, United Kingdom 17:25 to 17:32
CREST 2- novel design and goals William Gray, New York, United States 17:32 to 17:39
ACST-2 results Alison Halliday, Oxford, United Kingdom 17:39 to 17:46
Current insights into carotid plaque stabilisation Frans Moll, Utrecht, Netherlands 17:46 to 17:53
Interactive audience participation 17:53 to 18:08
Sunday 06 April

Chairman Andrew Holden, Auckland, New Zealand 08:00 to 08:14
CT imaging with case planning before and imaging after abdominal aortic aneurysm repair St?phan Haulon, Lille, France 08:07 to 08:14
The value of hybrid suite for accurate deployment Jan Brunkwall, Koln, Germany 08:14 to 08:21
The 2D / 3D quandary during deployment Jean-Pierre Becquemin, Creteil, France 08:21 to 08:28
How far away is 3D imaging at deployment? Dittmar Boeckler, Heidelberg, Germany 08:28 to 08:35
MR imaging for imaging before and after abdominal aortic aneurysm repair Tim Leiner, Utrecht, Netherlands 08:35 to 08:42
Follow-up imaging and step down to ultrasound Paul Hayes, Cambridge, United Kingdom 08:42 to 08:49
Chairman Frans Moll, Utrecht, Netherlands 09:06 to 09:56
The prevention of intra-abdominal hypertension Jan de Waele, Ghent, Belgium 09:06 to 09:13
The diagnosis and recognition of ischaemic bowel Mario Lachat, Zurich, Switzerland 09:13 to 09:20
Factors associated with intra-abdominal hypertension and abdominal compartment syndrome Anders Wanhainen, Uppsala, Sweden 09:20 to 09:27
Management of this following EVAR or open repair Martin Bjorck, Uppsala, Sweden 09:27 to 09:34
Critical care management of abdominal compartment syndrome in 2014 Jan de Waele, Ghent, Belgium 09:34 to 09:41
Interactive audience participation and consensus vote 09:41 to 09:56
Chairman Matt Thompson, London, United Kingdom 10:30 to 11:20
Individual or centre reporting Ian Loftus, London, United Kingdom 10:30 to 10:40
VASCUNET European Experience Tim Lees, Newcastle upon Tyne, United Kingdom 10:40 to 10:50
Risk aversion ? the medico-legal perspective Natalie Hayes, London, United Kingdom 10:50 to 11:00
Smoking prevalence variation between Western and Eastern Europe Edward Choke, West Bridgford, United Kingdom 11:00 to 11:10
Interactive audience participation and consensus vote 11:10 to 11:20
The importance of radiation dosage exposure to patient and operator Johannes Gahlen, Ludwigsburg, Germany 11:20 to 11:30
Chairman Matt Thompson, London, United Kingdom 11:20 to 11:55
Novel X-ray system to reduce radiation dose for patient and staff during endovascular procedures Olivier Koning, Hertogenbosch, Netherlands 11:30 to 11:40
Invited commentary and panel discussion Lindsay Machan, Vancouver, Canada 11:40 to 11:45
Interactive audience participation 11:45 to 11:55
Chairman Roger Greenhalgh, London, United Kingdom 11:55 to 12:30
Complex anatomy- challenges with current EVAR devices Giovanni Torsello, Muenster, Germany 11:55 to 12:05
INCRAFT 2-year data INNOVATION trial Giovanni Pratesi, Florence, Italy 12:05 to 12:15
Interactive audience participation 12:15 to 12:30
Chairman Peter Taylor, London, United Kingdom 13:30 to 14:45
What a surgeon should know about familial abdominal aortic aneurysm Janet Powell, London, United Kingdom 13:30 to 13:40
The treatment of inflammatory aortic aneurysm Justin Mason, London, United Kingdom 13:40 to 13:50
The problem of EVAR limb occlusion Jean Bismuth, Houston, United States 14:00 to 14:10
New off-the-shelf iliac branched graft Piergiorgio Cao, Rome, Italy 14:10 to 14:20
Graft limb occlusion after EVAR - a current review Frank Criado, Baltimore, United States 14:20 to 14:30
Interactive audience participation 14:30 to 14:45
Updating cost effectiveness and revisiting surveillance intervals Matthew Glover, Uxbridge, United Kingdom 14:45 to 14:55
Targeted population screening for abdominal aortic aneurysm Ian Loftus, London, United Kingdom 14:55 to 15:05
The implication of declining prevalence of abdominal aortic aneurysm Frank Lederle, Minneapolis, United States 15:05 to 15:15
Interactive audience participation 15:15 to 15:30
Chairman Roger Greenhalgh, London, United Kingdom 16:30 to 18:30
Against the motion: EVAR rarely needs follow-up Matt Thompson, London, United Kingdom 16:35 to 16:40
Interactive audience participation and consensus vote 16:40 to 16:50
For the motion: Type II endoleaks are really type I endoleaks in disguise Robert Morgan, London, United Kingdom 16:50 to 16:55
Against the motion: Type II endoleaks are really type I endoleaks in disguise Frans Moll, Utrecht, Netherlands 16:55 to 17:00
Interactive audience participation and consensus vote 17:00 to 17:10
Systematic review for type II endoleak after EVAR Robert Sayers, Leicester, United Kingdom 17:10 to 17:18
Endovascular anchors in the management of type I endoleak William Jordan, Birmingham, United States 17:18 to 17:26
The PANDORA study on latest generation device durability over 5 years Giovanni Torsello, Muenster, Germany 17:26 to 17:34
Novel sealing technology improves EVAR Syed Hussain, Peoria, United States 17:34 to 17:42
Interactive audience participation and consensus vote 17:42 to 17:50
Lower profile devices in women Dierk Scheinert, Leipzig, Germany 17:50 to 17:58
Patient selection for abdominal aortic aneurysm repair, EVAR, minilaparotomy and open repair and effect on post operative mobilisiation. Do we need a trial? Ralf Kolvenbach, D?sseldorf, Germany 17:58 to 18:06
Effective treatment of hostile anatomy at the aortic neck Dittmar Boeckler, Heidelberg, Germany 18:06 to 18:14
Outcomes of EVAR in the Danish cohort study 2007-2010 Lars Lonn, Copenhagen, Denmark 18:14 to 18:22
Interactive audience participation and consensus vote 18:22 to 18:30
Monday 07 April

Chairman Andrew Holden, Auckland, New Zealand 08:00 to 08:31
Imaging requirements for thoracic aorta assessment Hans-Christoph Becker, Munich, Germany 08:00 to 08:07
Importance of biomechanics for ascending aortic endografts Rachel Clough, London, United Kingdom 08:07 to 08:14
Computational Fluid Dynamics- evaluation of branched stent grafts Herv Rousseau, Toulouse, France 08:14 to 08:21
Interactive audience participation and consensus vote 08:21 to 08:31
Evolving indications for TEVAR in the ascending aorta Rodney White, Torrance, United States 08:31 to 08:38
New generation devices to beat open surgery for the aortic arch Dittmar Boeckler, Heidelberg, Germany 08:38 to 08:45
Branched endograft solutions and role of proximal scallops Mo Hamady, London, United Kingdom 08:45 to 08:52
Interactive audience participation and consensus vote 08:52 to 09:02
Diagnosis imaging characteristics Benjamin W Starnes, Mercer Island, United States 09:02 to 09:10
The significance of the imaging finding of intramural thrombus Michael Dake, Stanford, United States 09:10 to 09:18
Deployment and use of intravascular ultrasound (IVUS) Benjamin W Starnes, Mercer Island, United States 09:18 to 09:26
The effect of coverage of the left subclavian artery after TEVAR Ali Azizzadeh, Houston, United States 09:26 to 09:34
Follow-up policy Martin Bjorck, Uppsala, Sweden 09:34 to 09:42
Interactive audience participation and consensus vote 09:42 to 09:57
Chairman Frans Moll, Utrecht, Netherlands 10:30 to 12:25
US DISSECTION trial for acute complicated type B aortic dissections - one-year results Rodney White, Torrance, United States 10:30 to 10:40
Lessons from the IRAD Registry and beyond - who and how to treat patients Santi Trimarchi, San Donato Milanese, Italy 10:40 to 10:50
The need to define success of treatment strategy Piergiorgio Cao, Rome, Italy 10:50 to 11:00
Interactive audience participation and consensus vote 11:00 to 11:15
For the motion: For uncomplicated type B dissections, early intervention is indicated Christoph Nienaber, Rostock, Germany 11:15 to 11:20
For the motion: For uncomplicated type B dissections, early intervention is indicated Jan Brunkwall, Koln, Germany 11:20 to 11:25
Against the motion: For uncomplicated type B dissections, early intervention is indicated Peter Taylor, London, United Kingdom 11:30 to 11:35
Against the motion: For uncomplicated type B dissections, early intervention is indicated Richard Gibbs, London, United Kingdom 11:30 to 11:35
Timing of intervention for type B aortic dissection matters Matt Thompson, London, United Kingdom 11:50 to 12:00
DISSECT: A new classification for aortic dissection Michael Dake, Stanford, United States 12:00 to 12:10
Interactive audience participation and consensus vote 12:10 to 12:25
Chairman Roger Greenhalgh, London, United Kingdom 13:30 to 13:55
MONA LSA branched device results Frank Arko, Charlotte, United States 13:30 to 13:40
First case experience with Gore TAG thoracic branch endoprosthesis Michael Dake, Stanford, United States 13:40 to 13:50
Interactive audience participation and consensus vote 13:50 to 13:55
Chairman Peter Taylor, London, United Kingdom 13:55 to 14:59
Haemodynamic considerations in the management of dissecting aneurysm Juan Carlos Parodi, San Isidro, Argentina 13:55 to 14:04
Chronological remodelling of the descending thoracic aorta after TEVAR Toru Kuratani, Osaka, Japan 14:04 to 14:13
Computational Fluid Dynamics- evaluation of the thoracic multilayer stent Herv Rousseau, Toulouse, France 14:13 to 14:22
Interactive audience participation and consensus vote 14:22 to 14:29
For the motion: Flow-diverting stents have a place in my practice Herv Rousseau, Toulouse, France 14:29 to 14:34
For the motion: Flow-diverting stents have a place in my practice Christos Liapis, Athens, Greece 14:34 to 14:39
Against the motion: Flow-diverting stents have a place in my practice Ralf Kolvenbach, D?sseldorf, Germany 14:39 to 14:44
Against the motion: Flow-diverting stents have a place in my practice Mark Fillinger, Lebanon, United States 14:44 to 14:49
Interactive audience participation and consensus vote 14:49 to 14:59
Management of infected endoprosthesis Roberto Chiesa, Milan, Italy 14:59 to 15:07
Fenestrated and branched grafts vs. open surgery ? update of the French trial Jean-Pierre Becquemin, Creteil, France 15:07 to 15:15
The infra-renal/supra-renal fixation controversy Michel Makaroun, Pittsburgh, United States 15:15 to 15:23
Interactive audience participation and consensus vote 15:23 to 15:30
Chairman Matt Thompson, London, United Kingdom 16:30 to 17:04
Sutureless renal artery Hybrid bypass during open surgery Roberto Chiesa, Milan, Italy 16:30 to 16:38
Failed off-the-shelf fenestrated EVAR and redo Timothy Resch, Malmo, Sweden 16:38 to 16:46
Recovery after juxta-renal and thoraco-abdominal repair Ralf Kolvenbach, D?sseldorf, Germany 16:46 to 16:54
Interactive audience participation and consensus vote 16:54 to 17:04
Outcomes of aneurysm repair in patients with renal disease Michel Makaroun, Pittsburgh, United States 17:04 to 17:12
Renal function decline after EVAR Franco Grego, Padua, Italy 17:12 to 17:20
Interactive audience participation and consensus vote 17:20 to 17:35
Chairman Janet Powell, London, United Kingdom 17:35 to 18:29
Aortic calcification and rupture risk Clark Zeebregts, Groningen, Netherlands 17:35 to 17:43
The benefits of improved anaesthesia and of fast track mobilisation after open and EVAR for ruptured aortic aneurysms Sebastian Debus, Hamburg, Germany 17:43 to 17:51
SWEDVASC Registry ? comparisons of primary EVAR strategy or primary open strategy for ruptured abdominal aortic aneurysms Kevin Mani, Uppsala, Sweden 17:51 to 17:59
Interactive audience participation and consensus vote 17:59 to 18:04
The quality improvement opportunities following the IMPROVE trial Matt Thompson, London, United Kingdom 18:04 to 18:14
Invited commentary Frank Veith, New York, United States 18:14 to 18:19
Interactive audience participation and consensus vote 18:19 to 18:29
Tuesday 08 April

Chairman Ian Franklin, London, United Kingdom 08:00 to 09:07
Nice Guidelines Alun Davies, London, United States 08:00 to 08:06
Interactive audience participation and consensus vote 08:06 to 08:10
For the motion: Pelvic vein reflux must be treated before addressing leg veins Joe Brookes, London, United Kingdom 08:10 to 08:15
Against the motion: Pelvic vein reflux must be treated before addressing leg veins Jonothan Earnshaw, London, United Kingdom 08:15 to 08:20
Interactive audience participation and consensus vote 08:20 to 08:25
How to treat vulval veins after pelvic embolisation Barrie Price, Guildford, United Kingdom 08:25 to 08:31
Pelvic venous congestion causes haemorrhoids Judith Holdstock, Godalming, United Kingdom 08:31 to 08:37
Interactive audience participation 08:37 to 08:42
Ultrasound choices during vein procedures - hand held duplex or IVUS? Steve Elias, Englewood, United States 08:42 to 08:48
Interactive audience participation 08:48 to 08:52
For the motion: Duplex scanning is mandatory after treatment for saphenous reflux Mark Whiteley, Guildford, United Kingdom 08:52 to 08:57
Against the motion: Duplex scanning is mandatory after treatment for saphenous reflux Lowell Kabnick, Morristown, United States 08:57 to 09:02
Interactive audience participation 09:02 to 09:07
For the motion: There is no indication for groin exploration for recurrent varicose veins Eddie Chaloner, London, United Kingdom 09:07 to 09:12
Against the motion: There is no indication for groin exploration for recurrent varicose veins John Scurr, London, United Kingdom 09:12 to 09:17
Interactive audience participation and consensus vote 09:17 to 09:22
Is all heat the same and does catheter design matter? Mark Whiteley, Guildford, United Kingdom 09:22 to 09:28
Endovascular radiofrequency with Venefit Stephen Black, London, United Kingdom 09:28 to 09:34
EVRF for the treatment of veins, small and large Attila Szabo, Budapest, Hungary 09:34 to 09:40
Gentle ablation with Celon RFITT technology Stefan Schulte, K?ln, Germany 09:40 to 09:46
Interactive audience participation 09:46 to 09:56
Chairman Mark Whiteley, Guildford, United Kingdom 10:30 to 12:30
ClariVein Michel Reijnen, Arnhem, Netherlands 10:30 to 10:36
EVLT NeverTouch Lowell Kabnick, Morristown, United States 10:36 to 10:42
EVLT for perforating veins with NTD Mark Whiteley, Guildford, United Kingdom 10:42 to 10:48
EVLT ? Biolitec Michael Gough, Leeds, United Kingdom 10:48 to 10:54
CLASS Trial Julie Brittenden, Aberdeen, United Kingdom 10:54 to 11:00
Glue Kathleen Gibson, Bellevue, United States 11:00 to 11:06
Discussion: radiofrequency, laser and glue ? the consensus 11:06 to 11:21
Catheter-directed foam with tumescence Attilio Cavezzi, San Benedetto del Tronto, Italy 11:21 to 11:27
The difference in wall penetration between STD and polidocanol Michael Gough, Leeds, United Kingdom 11:27 to 11:33
Sclerosant selection Philip Coleridge-Smith, London, United Kingdom 11:33 to 11:39
Standardised foam is key David Wright, Camberley, United Kingdom 11:39 to 11:45
Interactive audience participation 11:45 to 12:00
For the motion: Air is the best gas for making foam Katy Darvall, Exeter, United Kingdom 12:00 to 12:05
Against the motion: Air is the best gas for making foam Attilio Cavezzi, San Benedetto del Tronto, Italy 12:05 to 12:10
Interactive audience participation and consensus vote 12:10 to 12:15
For ASVAL: ASVAL vs. CHIVA Paul Pittaluga, Nice, France 12:15 to 12:20
For CHIVA: ASVAL vs. CHIVA Claude Franceschi, Paris, France 12:20 to 12:25
Chairman Alun Davies, London, United Kingdom 13:30 to 13:36
The place of concomitant phlebectomy Tristan Lane, London, United Kingdom 13:30 to 13:36
Consensus panel on current best methods of correcting superficial varicose veins- radiofrequency vs. laser vs. mechanoablation vs. sclerotherapy vs. surgery 13:36 to 13:51
Pneumatic pressure device for prevention of deep venous thrombosis Martin Dennis, Edinburgh, United Kingdom 13:51 to 13:57
Interactive audience participation 13:57 to 14:01
Reliable reporting systemd for deep vein thrombosis Gerry Stansby, Newcastle, United Kingdom 14:01 to 14:07
Catheter-based interventions for deep vein thrombosis: which is the best? Iris Baumgartner, Bern, Switzerland 14:07 to 14:13
EHIT, EFIT, EGIT: a new word is needed for therapy induced thrombosis James A Lawson, Alkmaar, Netherlands 14:13 to 14:19
Interactive audience participation 14:19 to 14:29
The role of truncal ablation in venous ulceration: is timing key? Manj Gohel, Cambridge, United Kingdom 14:29 to 14:35
Stent design is critical for deep vein recanalisation Gerard O'Sullivan, Galway, Ireland 14:35 to 14:41
The deep venous valve management in the future Hayley Moore, London, United Kingdom 14:41 to 14:47
Isolated pharmacomechanical thrombectomy Gerard O'Sullivan, Galway, Ireland 14:47 to 14:53
Deep venous reconstruction Stephen Black, London, United Kingdom 14:53 to 14:59
Image fusion with MRV for 3D guidance of deep venous interventions Michiel De Haan, Maastricht, Netherlands 14:59 to 15:05
Interactive audience participation 15:05 to 15:20
ABBOTT VASCULAR SATELLITE Saturday 05 April

Chairman Enrique Puras Mallagray, Madrid, Spain 10:00 to 10:30
ABBOTT VASCULAR SATELLITE: Torsion, flexion, compression- how does a stent deal with multiple forces? Gerrit Krupski-Berdien, Reinbek, Germany 10:00 to 10:30
ABBOTT VASCULAR SATELLITE: How to optimise outcomes in the superficial femoral artery? Jan Peter Goltz, L?beck, Germany 10:00 to 10:30
ABBOTT VASCULAR SATELLITE: Vascular mimetic technology- what do the outcomes show? Peter Goverde, Antwerp, Belgium 10:00 to 10:30
Monday 07 April

Chairman Matt Thompson, London, United Kingdom 10:00 to 10:30
ABBOTT VASCULAR SATELLITE: What do the data show? Ian Loftus, London, United Kingdom 10:00 to 10:30
ABBOTT VASCULAR SATELLITE: Prostar in large holes Matt Thompson, London, United Kingdom 10:00 to 10:30
ABBOTT VASCULAR SATELLITE: Proglide tips and tricks Mario Lachat, Zurich, Switzerland 10:00 to 10:30
CORDIS ABDOMINAL AORTIC SATELLITE Monday 07 April

Chairman Giovanni Torsello, Muenster, Germany 15:30 to 16:00
CORDIS ABDOMINAL AORTIC SATELLITE: Global Incraft clinical program Jan Brunkwall, Koln, Germany 15:30 to 16:00
CORDIS ABDOMINAL AORTIC SATELLITE: Technical features of the INCRAFT AAA stent graft Luca Bertogilo, Milan, Italy 15:30 to 16:00
COOK ABDOMINAL AORTIC SATELLITE Monday 07 April

Chairman St?phan Haulon, Lille, France 16:00 to 16:30
COOK ABDOMINAL AORTIC SATELLITE: Aortic aneurysm sac enlargement after EVAR Andres Schanzer, Worcester, United States 16:00 to 16:30
COOK ABDOMINAL AORTIC SATELLITE: Signs of a compromised aortic seal zone Tilo Kolbel, Hamburg, Germany 16:00 to 16:30
COOK ABDOMINAL AORTIC SATELLITE: Beyond standard EVAR - the right device for the right patient Carlos H Timaran, Dallas, United States 16:00 to 16:30
ENDOLOGIX SATELLITE Sunday 06 April

Chairman Matt Thompson, London, United Kingdom 15:30 to 16:30
ENDOLOGIX SATELLITE: Clinical outcomes with EVAS - real-world European experience and the EVAS Global Registry Matt Thompson, London, United Kingdom 15:30 to 16:30
ENDOLOGIX SATELLITE: EVAR and EVAS: what is the difference? Dittmar Boeckler, Heidelberg, Germany 15:30 to 16:30
ENDOLOGIX SATELLITE: EVAS - integration into practice Paul Hayes, Cambridge, United Kingdom 15:30 to 16:30
ENDOLOGIX SATELLITE: EVAS - case reviews Michel Reijnen, Arnhem, Netherlands 15:30 to 16:30
ENDOLOGIX SATELLITE: EVAS for difficult cases Andrew Holden, Auckland, New Zealand 15:30 to 16:30
GORE SATELLITE Saturday 05 April

Chairman Markus Steinbauer, Regensburg, Germany 15:30 to 16:00
GORE SATELLITE: Randomised controlled trial of endoluminal bypass vs. bare metal stent for long superficial femoral artery lesions Martin Funovics, Vienna, Austria 15:30 to 16:00
GORE SATELLITE: Heparin bonded ePTFE outperforms standard ePTFE after 4 years Russell H Samson, Sarasota, United States 15:30 to 16:00
Sunday 06 April

Chairman Dittmar Boeckler, Heidelberg, Germany 10:00 to 10:30
GORE SATELLITE: Moving Beyond On-Label Registries ? Using the GREAT Registry to look at how EVAR / TEVAR technology is really used Ross Milner, Chicago, United States 10:00 to 10:30
GORE SATELLITE: A new iliac branch system for aorto-iliac and common iliac aneurysms Robert Fisher, Liverpool, United Kingdom 10:00 to 10:30
MAQUET SATELLITE Saturday 05 April

Chairman Eric Verhoeven, Nuremberg, Germany 12:30 to 13:30
MAQUET SATELLITE: Preliminary study results of the first antimicrobial graft coated with Silver acetate and triclosan Max Zegelman, Frankfurt/Main, Germany 12:30 to 13:30
MAQUET SATELLITE: Results of the FINEST and PERFECTION trial Afshin Assadian, Vienna, Austria 12:30 to 13:30
MAQUET SATELLITE: How to treat aorto-iliac disease Peter Goverde, Antwerp, Belgium 12:30 to 13:30
MAQUET SATELLITE: Advanced technique with balloon expandable covered stent Giovanni Torsello, Muenster, Germany 12:30 to 13:30
MEDTRONIC SATELLITE Sunday 06 April

Chairman Ross Milner, Chicago, United States 12:30 to 13:30
MEDTRONIC SATELLITE: Do new EVAR devices reduce the need for aortic related re-interventions Philippe Cuypers, Eindhoven, Netherlands 12:30 to 13:30
MEDTRONIC SATELLITE: Device design and influence on hostile neck outcomes: How far can we go? Hence Verhagen, Rotterdam, Netherlands 12:30 to 13:30
MEDTRONIC SATELLITE: Evolving TEVAR durability for TAA: Insights from Valor and Valor II trials Gilbert Upchurch, Charlottesville, United States 12:30 to 13:30
MEDTRONIC SATELLITE: Aortic pathologies and impact on TEVAR outcomes - lesson learned from more than 1000 TEVAR patients Registry Matt Thompson, London, United Kingdom 12:30 to 13:30
VASCUTEK SATELLITE Monday 07 April

Chairman Clark Zeebregts, Groningen, Netherlands 12:30 to 13:30
VASCUTEK SATELLITE: Anaconda stent graft system - Phase 2 IDE study 12-month results Randy Moore, Calgary, Canada 12:30 to 13:30
VASCUTEK SATELLITE: The Thoraflex? hybrid frozen elephant trunk device ? the Bologna experience Roberto Di Bartolomeo, Bologna, Italy 12:30 to 13:30
VASCUTEK SATELLITE: More real world FEVAR data from the UK fenestrated Anaconda? Registry results - what next? Peter Bungay, Derby, United Kingdom 12:30 to 13:30